Research programme: eye disorder therapies - Bicycle Therapeutics/ThromboGenicsAlternative Names: TG-758; THR 149
Latest Information Update: 16 Oct 2014
At a glance
- Originator Bicycle Therapeutics
- Developer Bicycle Therapeutics; ThromboGenics
- Class Peptides
- Mechanism of Action Capillary permeability modulators; Plasma-kallikrein-inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetic macular oedema; Eye disorders